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What’s Known (word count 50 words up to two bullets) 
• After infection by Mycobacterium tuberculosis, within 2 years 5% of individuals develop 
clinical manifestations of the primary tuberculosis. 5-10% of those infected during the 
course of their life develops secondary tuberculosis.  
• There is an assumption that different genetic factors affect the risk of primary 
tuberculosis and secondary tuberculosis but genetic studies considering these stages 
of the disease separately are limited. 
What’s New (word count 50 words up to two bullets) 
• In our study, for the first time, we identified an association between polymorphisms of 
PACRG (rs10945890) and CD80 (rs1880661) genes and the development of different 
stages of tuberculosis infection. These genes have never been studies before regarding 
TB.  
• We found a novel proof that predisposition to different forms of TB infection are under 




Background: Tuberculosis (TB) is one of the most significant health care problems 
worldwide. Host genetics play an important role in the development of TB in humans. The 
disease progresses through several stages, each can be under the control of different genes. The 
precise genes influencing different stages of the disease are not yet identified. The aim of the 
current study was to analyse associations between primary and secondary TB and 
polymorphisms of novel TB susceptibility candidate genes – CD79A, HCST, CXCR4, CD4, 
CD80, CP, PACRG, and CD69.  
Materials and methods: A total of 362 TB patients from Siberian region of Russia were 
studied, including 130 cases with primary TB and 232 cases with secondary TB, as well as 445 
healthy controls. The study was performed at the Research Institute of Medical Genetics, Tomsk 
NRMC, Tomsk, Russia, between July 2015 and November 2016. Genotyping was carried out 
using MALDI-TOF mass-spectrometry and PCR-RFLP. Association between the SNPs and TB 
was assessed using logistic regression adjusting for covariates (age and gender). Multiple testing 
issue was addressed via experiment-wise permutation approach. Statistical significance threshold 
was p<0.05 for permutation p-values. Analysis was done in R 3.2 statistical software. 
Results: An association was established between the rs1880661 variant of CD80 gene and 
secondary TB and rs10945890 variant of PACRG gene and both primary and secondary TB. 
However, the same allele of PACRG appeared to be both a risk factor for reactivation (secondary 
TB), while being protective against primary infection.  
Conclusion: The results suggest that CD80 and PACRG genes are associated with 
susceptibility to different forms of TB infection in the Russian population.  





Tuberculosis (TB) remains one of the most dangerous infectious human diseases. In 
2015, 10.4 million new TB cases we estimated and 1.8 million people (including 0.4 million 
people with HIV) died as a result of the disease.1 Importantly, infection of a human with M. 
tuberculosis is not enough for TB to progress into a clinical disease. Only about 10% of infected 
cases develop active disease, while the rest remain latently infected or completely get rid of 
bacteria. The outcome of the infection is dictated by such factors as the environment, virulence 
of bacterial strain, infection load, as well as individual immune system features of the host which 
are strongly genetically determined. 
The involvement of certain regions of the human genome in the susceptibility to TB has 
been the target of active research over the past decades. As the result of candidate genes studies, 
many genes encoding enzymes with immune functions have been identified, some of them have 
been shown to have a "major gene" effect on TB susceptibility.2 Thus far, 10 genome-wide 
association studies (GWAS) for TB have been published that identified more than 20 genes 
associated with the disease, including ASAP1, AGMO, FOXP1 involved in the functioning of 
macrophages and dendritic cells.3 
Also, as the result of the studies of atypical familial mycobacteriosis, rare mutations in 
IL12B/IFNG genes responsible for anti-infectious immunity were revealed. The mutations cause 
the development of severe, and usually lethal disease in response to non-pathogenic or mildly 
pathogenic bacteria including M. bovis, M. avium, and S. enterica. These studies played an 
important role in the identification of genes involved in immune response against mycobacteria.  
Despite the remarkable achievements in understanding the pathogenesis of TB, there are 
substantial unresolved issues in diagnostics, prophylaxis and treatment of the disease.  Lack of 
understanding of the mechanisms of reactivation of latent infection - which creates a huge 
reservoir of the dangerous disease distribution for many years, is especially worrying.4 The 
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existent diagnostics tools are based on the analysis of M. tuberculosis patients’ sputum and X-ray 
examination; however, their disadvantages include a delay in the finding of bacteria in sputum, 
thus delaying the treatment.5 Also, there is a lack of information about molecular genetic 
mechanisms by which susceptibility to TB converts to the disease, in turn, resulting in an slow 
progress in the development of effective treatment and prevention strategies. 
More recently, systems biology and bioinformatics approaches are being used for the 
discovery of novel anti-tuberculosis drug targets. In particular, bioinformatics strategies are 
directed towards the studies of “host-pathogen” interactions6-7, because it is known that the 
success of M. tuberculosis is driven by its capability to modify human immune response8, with 
different strains of bacteria being able to induce various patterns of the host immune response.9  
Likely, an approach based on the revelation of functional interactions between 
genes/proteins involved in gene networks would improve our understanding of the nature of the 
dynamic reaction to infection and would help establish most important molecular participants in 
the disease development. Thanks to the network approach describing protein-protein interactions 
for the genes differentially expressed in TB patients, a pattern of genes called “common core” 
for the disease was discovered including genes important in immune response, such as STAT1, 
PLSCR1, C1QB, OAS1, GBP2 and PSMB9.10 
In our previous study, we carried out a reconstruction of associative network for TB and 
revealed novel candidate genes including CD4, CD69, CD79, CD80, MUC16, HCST, ADA, CP, 
SPP1, CXCR4, AGER, and PACRG.11 As a follow up, in the current study we analysed 
regulatory polymorphisms for the genes from the associative network to assess their 
pathogenetic significance for different stages of TB infection. 
Material and methods 
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The study was approved by the Ethics Committee of the Research Institute of Medical 
Genetics of Tomsk NRMC and signed informed consent was obtained from all participants. The 
study was performed at the Research Institute of Medical Genetics, Tomsk NRMC, Tomsk, 
Russia, between July 2015 and November 2016. 
The diagnosis of TB was established on the basis of sputum microscopy data with 
mandatory X-ray examination of the lungs to determine the form of the disease and the 
prevalence of a specific process. HIV-positive patients were excluded. Control group included 
healthy individuals without history of TB. The participants were predominantly Russians settled 
in the city of Tomsk or Tomsk Region, West Siberia, Russia. The demographic and clinical data 
for each patient were collected. 
DNA samples were retrieved for 362 TB patients and 445 healthy controls from the DNA 
Bank of the Research Institute of Medical Genetics of Tomsk NRMC (Table 1). The sample of 
TB patients included 130 cases with primary TB and 232 with reactivation. The control group 
for primary TB was deliberately older as compared to the cases (16.6±15.0 vs 39.5±17.0) to 
ensure that the control individuals were not affected by TB up until adulthood.  
For the genotyping, we chose 14 single nucleotide polymorphisms (SNPs) in 8 genes in 
which regulatory capacity was established using data from RegulomeDB database (Table 2). The 
database classifies SNPs into classes according to the combined status of overlap with functional 
categories such as transcription factor binding sites, DNase I hypersensitivity and promoters, and 
assigns respective score from 1 to 6 with the smaller score meaning higher functional impact of a 
SNP (http://regulomedb.org/).  
Genotyping was carried out using MALDI-TOF mass-spectrometry and PCR-RFLP. For 
MALDI-TOF mass-spectrometry we used iPLEX GOLD kits (Agena Bioscience) and 
MassARRAY Analyzer 4 (Seqeunom). Genotype calls were done automatically by 
MassARRAY Typer 4 software. PCR-RFLP was carried out using custom primers and specific 
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restriction endonucleases (Fermentas and Sibenzyme) (Table 3). All  analyses were carried out in 
the “Medical Genomics” Core Facilities of the Research Institute of Medical Genetics. 
Association between the SNPs and TB was assessed using logistic regression adjusting 
for covariates (age and gender). Additive, dominant and recessive genetic models were tested. In 
dominant model, rare allele homo- and heterozygotes are tested against common allele 
homozygotes. In the recessive model, common allele homo- and heterozygotes were tested 
against rare allele homozygotes. The additive model corresponds to a trend test for the genotypes 
with the genotypes coded as 0, 1, or 2 to reflect the minor allele counts. The best model was 
chosen using Akaike Information Criterion. The SNP effects were quantified with the odds ratio 
(OR) and 95% confidence intervals. Multiple testing was addressed using experiment-wise 
permutations. Models with permutation p<0.05 were considered statistically significant. 
Statistical analysis was carried out in R 3.2 statistical software. 
Results  
We chose new candidate genes of special interest based on the results of our previous 
study: CD4, CD69, CD79, CD80, MUC16, HCST, ADA, CP, SPP1, CXCR4, AGER, and 
PACRG.11 To the best of our knowledge, these genes have never been studied with respect to 
TB. To select SNPs in these genes, we took into account such parameters as 1) localization in the 
5 'region of the gene; 2) the global frequency of the minor allele ≥5%; 3) SNPs with high 
confidence of functional consequence in genes region using RegulomeDB. Accordingly, we 
selected for the genotyping 14 SNPs in 8 genes (CD4, CD69, CD79, CD80, HCST, CP, CXCR4, 
and PACRG; Table 2). 
In the control group as well as in patients group, all SNPs met Hardy-Weinberg 
equilibrium expectation. The rs75343219 SNP in CD69 was monomorphic in Russians and 
excluded from subsequent analysis.  
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An association was established between TB and the rs1880661 polymorphism in CD80 
gene (Table 4). When primary and secondary TB were considered separately, an association was 
found between this polymorphism and secondary TB only. The prevalence of the rs1880661*C 
allele of CD80 gene in patient with secondary TB was 40.9%, in patient with primary TB it was 
44.7% and in the control group it was 46,8%. 
Also, the rs10945890 variant in PACRG was associated both with primary and secondary 
TB; however, there was a recessive effect of the polymorphism for primary TB and dominant 
effect for secondary TB. The same allele rs10945890*C of the gene PACRG was associated with 
the decreased risk of primary TB (OR=0.26 [0.04;0.89]; p=0.03), but with the increased risk of 
reactivation (OR=1.47 [1.02;2.13]; р=0.04). In patients with primary TB, the frequency of the 
rs10945890*C allele of PACRG gene was 20.5%, in patient with secondary TB it was 28.6% and 
in the control group it was 25.6%. 
Discussion 
We carried out an analysis of association between different stages of TB infection and 
potential regulatory SNPs in CD4, CD69, CD79, CD80, HCST, CP, CXCR4, and PACRG genes. 
Most of the proteins  encoded for by these genes are involved in immune signaling and are 
responsible for the effectiveness of immune reactions to the invasion of the pathogen. 
Polymorphisms in CD80 and PACRG genes were found to be associated with different stages of 
TB in Russians. 
CD80 gene encodes a transmembrane receptor, a co-stimulator for antigen presentation 
by macrophages and dendritic cells. Its expression is reduced in mycobacterial infection, the 
mechanism by which mycobacteria supresses adaptive immune response.12 According to our 
previous data, CD80 is the most promising candidate gene out of the lot from TB associative 
network.11 We studied three SNPs in this gene (rs59569688, rs3915165, rs1880661) and found 
that rs1880661 is associated with secondary TB. This polymorphism is an expression 
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quantitative trait locus (eQTL) and influences the expression of CD80 and ADPRH in a tissue-
specific manner (Figure. 1). The SNP is associated with differential expression of CD80 in 
dendritic cells before and after mycobacterial infection.13 The association between TB and this 
SNP was established for the first time in the current study; however, there are other 
polymorphisms in CD80 associated with immune-mediated diseases, such as celiac disease 
(rs11712165)14 and primary biliary cirrhosis  (rs2293370).15 
The PACRG gene encodes parkin co-regulated protein and located on 6q26 the cluster 
with related gene PARK2. These genes have a common regulatory region and are involved in 
ubiquitin-mediated protein degradation. They were found to be important for susceptibility to 
diseases caused by M. ulcerans and M. leprae.16 The variant of PACRG associated with TB in 
the current study (rs10945890) has never been studied for association with TB or other diseases. 
It is also challenging to explain why the same allele of the gene is associated with the decreased 
risk of primary TB (OR=0.26 [0.04;0.89]; p=0.03), but increases the risk of reactivation 
(OR=1.47 [1.02;2.13]; р=0.04). Functional studies as well as replication in other populations will 
be required to delineate this. 
No other studied genes were found to be associated with TB in the current study; 
however, their analysis in other populations may still be fruitful given their functional 
importance in TB pathogenesis.  
The CD69 gene located on 12p13.31 and encodes type II transmembrane glycoprotein. 
Increased expression of the CD69 gene is observed in TB patients.17 Polymorphism rs4763879 in 
this gene was found to be associated with type I diabetes.18  
The CD4 gene (12p13.31) encodes the membrane glycoprotein of T-lymphocytes which 
plays an important role in T-helper cell activation. The deficit of CD4+ T cells promotes 
susceptibility to M. tuberculosis infection.19 Except for the current study, polymorphisms of CD4 
gene have never been studied in TB susceptibility. 
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The CD79A gene encodes Ig-α protein expressed in B-lymphocytes. The protein is 
essential for immune pathogenesis of TB.20 The gene located on 19q13.2 and is associated with 
cancer21 however there are not studies of the polymorphisms of CD69 gene and susceptibility to 
TB. 
The HCST (DAP10) gene located on 19q13.12 encodes a transmembrane signaling 
adaptor containing the YxxM motif in its cytoplasmic domain. The expression of HCST gene 
was found repressed during late stages of infection in nonhuman primates infected by M. 
tuberculosis.22 This gene is of interest for the study of different stages of TB infection but the 
polymorphisms of this gene have never been studied in this respect. 
The CP gene encodes ceruloplasmin, a metalloprotein which binds up to 95% of blood 
cuprum. Copper along with other microelements are important in protecting against pathogenic 
microorganisms23, which underlies the antibacterial function of ceruloplasmin. Ceruloplasmin is 
an acute phase protein; its concentration, along with cuprum ions levels are elevated in lung TB 
patients.24 Defects in the CP can lead to a disruption of the binding and transport function of 
ceruloplasmin and, as a result, an increase in sensitivity to intracellular pathogens, such as 
mycobacteria. No studies of association between this gene variants and TB are available. 
The gene CXCR4 (2q22.1) encodes chemokine (CXC motif) receptor 4, CXCR4 is 
involved in angiogenesis induced by granuloma.25 The polymorphisms of gene CXCR4 rs2680880 
associated with overall survival from colorectal brain metastases diagnosis26, another SNP of this 
gene rs953387 links with juvenile idiopathic arthritis, an autoimmune disease.27 
Thus, the above genes are important for an effective immune response to the invasion of 
the pathogen, but they have not been extensively studied in TB. Thus, our study provides the first 
glance at these genes with regards to TB.  
The majority of genetic studies of TB are focused on establishing associations between 
the disease per se and genetic variants. However,  studies considering clinical forms or stages of 
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the disease are limited. The current study was carried out to reveal genetic factors associated 
with various stages of TB.  
In contemporary studies of TB, the major question is why immunity is able to control the 
infection in primary contact, but cannot prevent reactivation. High resistance to primary TB 
actually predisposes to the development of secondary TB.28 The majority of immunocompetent 
people would develop delayed hypersensitivity activating T-cells and Th1-immunity which 
effectively controls primary TB. However, this process has little effect on secondary TB, also 
neither immunization, nor natural infection result in immunity to secondary TB.29 This means 
that mycobacteria employs an effective strategy to avoid host immune response or even benefit 
from it.30  
Recently, it has been noted that the immune response characterised by elevated activity of 
CD4+ Т-cells and increased levels of IFN-γ causes the development of secondary TB thus 
contradicting with a widely accepted view that impaired immunity leads to reactivation of latent 
infection.31 Even though the risk of TB is increased when the immunity weakens, the disease 
aetiology in individuals with impaired immunity differs from the disease aetiology in 
immunocompetent people. The development of the disease in immunocompromised people is 
caused by an uncontrolled proliferation of the bacteria, while in individuals with healthy immune 
system, it is a damage of lung tissue that causes the development of active disease.32 These 
different mechanisms may be the basis for clinical heterogeneity of TB, therefore different genes 
can be involved. Thus, primary and secondary TB can be controlled by different host genes32-33, 
which is supported by the results of the current study.  
The advantage of the current study is the focus on the analysis of novel candidate genes 
and stratified analysis according to the stages of TB infection. However, the study has a 
limitation – the control group was significantly older than the cases. However, this was done to 
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avoid possible risk of TB in subsequent life of young individuals, if taken as control. Another 
limitation is the lack of replication sample. Thus, our findings require independent validation.  
Conclusion 
In summary, our data suggest that the studied polymorphisms in CD80 and PACRG genes 
affect susceptibility to different stages of TB infection (primary and secondary TB) in Russian 
patients. If replicated in independent samples, the mechanisms of the associations are to be 
disclosed in experimental studies. However, given that we analyzed SNPs from regulatory 
regions of the genes, the mechanisms are likely related to modulation of the gene expression.  
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Table 1 – Demographics of the studied individuals 
Group Number Mean age±SD, years р 
Tuberculosis* 362 29.0±17.4 4 x 10-17 
    
Females 125 23.0±16.3   
Males 232 32.3±17.1  
Primary tuberculosis 130 16.6±15.0 1.4 x 10-35 
    
Females 63 14.3±13.0  
Males 67 18.8±16.3  
Secondary tuberculosis 232 36.1±14.5 0.007 
    
Females 63 31.7±14.6  
Males 165 37.8±14.1  
Healthy control 445 39.5±17.0  
    
Females 273 38.3±17.2  
Males 172 41.5±16.7  
* Primary and secondary TB together; p value for Student’s t-test for comparison between 





Table 2 – List of studied SNPs with localization and Regulome DB scores. 





CXCR4  2q22.1 rs12691874 0.31 (A) 2:136122904 2a 
CD80 3q13.33 rs59569688 0.18 (T) 3:119559065 2b 
CD80 3q13.33 rs3915165 0.23 (T) 3:119560504 2b 
CD80 3q13.33 rs1880661 0.34 (G) 3:119560001 2b 
CP  3q23-q25 rs7623663 0.16 (T) 3:149224171 2b 
PACRG 6q26 rs12211969 0.13 (G) 6:163312136 2b 
PACRG 6q26 rs58627325 0.14 (A) 6:163309605 2a 
PACRG 6q26 rs6455894 0.20 (A) 6:163311988 2a 
PACRG  6q26  rs10945890 0.30 (C) 6:163308974 2b 
CD69 12p13.31 rs75343219 0.076 (G) 12:9761162 2b 
CD4 12p13.31 rs2855534 0.47 (G) 12:6789355 2b 
CD4 12p13.31 rs7296859 0.25 (C) 12:6784998 1f 
CD79A 19q13.2 rs10417985 0.40 (T) 19:41873065 2b 
HCST 19q13.12 rs11878547 0.09 (C) 19:35902284 2b 
Table 3 - Sequences of primers and methods of genotyping. 









rs10417985 ACGTTGGATGACTTGCCAGATATCCCACAG ACGTTGGATGTCTTTTCTGAGGCACAGAGC gggtGAGTGGCTAGGTCCAGG 
MALDI-TOF 
rs11878547 ACGTTGGATGTCTTCTCAGCGTTTCATGCC ACGTTGGATGGTAGGGCCAAGAAAATTTGC ctgtCCAAGAAAATTTGCTGATTAAATG 
MALDI-TOF 
rs12691874 ACGTTGGATGGGTGACCTCAGACAGCTATA ACGTTGGATGAAACTTGACAGTCCACAGGG caggCCACAGGGCTCTAGG 
MALDI-TOF 
rs2855534 ACGTTGGATGTGCCATCTTTTTCTTGCCGC ACGTTGGATGGAAAATGCCAAAGTCAAGGG gggtCTTAACAGTGGCAGTGACA 
MALDI-TOF 
rs59569688 ACGTTGGATGAAAGAGACTTATTCACCAG ACGTTGGATGAGACTGTGGTGAGCTATGGT aAGAATTTGTTTTTCTTAAGATAGAAT 
MALDI-TOF 
rs7296859 ACGTTGGATGTTGACTTCCAGGCCACAGAC ACGTTGGATGTTTGCAGATTCCAGACCCGA ccttaCACAGACTCACAGAGCTG 
MALDI-TOF 
rs7623663 ACGTTGGATGTTGTGGTAGTTACTCTTCTC ACGTTGGATGCCCCTCTCCCTCCTATTTAA GCATGTGGCAGGAAGT 
MALDI-TOF 
rs12211969 ACGTTGGATGGGGTTTATGCAATGGGCTC ACGTTGGATGTAGGCATGAAAGAGGTGGAC TGCAATGGGCTCTGTCCT 
MALDI-TOF 
rs3915165 ACGTTGGATGGGGTTTATGCAATGGGCTC ACGTTGGATGTAGGCATGAAAGAGGTGGAC TGCAATGGGCTCTGTCCT 
MALDI-TOF 
rs58627325 ACGTTGGATGTTCAAGCTTCCGAAAGCAGG ACGTTGGATGCTGAGTGAATCAGGAAATGG aAGGAAATGGTTAAGAGGTGA 
MALDI-TOF 
rs6455894 ACGTTGGATGTGGTCTATTCAGCTCTTGAC ACGTTGGATGGTCACTCATAAATGGTGCCT GTGCCTTTTGTCGGCATAT 
MALDI-TOF 
rs75343219 ACGTTGGATGAGTGGGATTTTCCCAGACTC ACGTTGGATGACTTAGATTATGCTGTCTCC ggtaCTGCCTTAAATTTCTAGAAAAC 
MALDI-TOF 











Table 4 – Statistically significant models for association between tuberculosis and the 
polymorphisms of PACRG (rs10945890) and CD80 (rs1880661) genes. 
Sample 
  
SNP Best model 
Risk 
allele 
% Effect OR [95% CI] P-
perm* 
Tuberculosis rs1880661 C 41.6 Dominant 0.68 [0.48;0.96] 0.03 
Primary 
tuberculosis 
rs10945890 C 20.5 Recessive 0.26 [0.04;0.89] 0.03 
Secondary 
tuberculosis 
rs10945890 C 28.6 Dominant 1.47 [1.02;2.13] 0.04 
rs1880661 C 40.9 Dominant 0.67 [0.46; 0.97] 0.04 










Figure 1 – GTEx box plot of CD80 and ADPRH genes expression for the cis-eQTL 
rs1880661. 
Box plots of gene expression profiles for CD80 (ENSG00000121594.7) in muscle tissue and 
ADPRH (ENSG00000144843.7) in adipose tissue expression by genotype (data of the GTEx 
project portal (http://www.gtexportal.org/home/)). Reference allele (risk allele) = C.  
 
